Missouri health system taps M*Modal for transcription, ICD-10 tech

Editorial Staff | | Health Exec | Digital Transformation

M*Modal, a developer of clinical documentation, computer-assisted coding (CAC) and speech understanding technologies, will provide its M*Modal Fluency for Coding workflow platform to Mercy Health System. This cloud-based application delivers workflow and CAC services, as well as ICD-10 support.

The new agreement enables M*Modal to deliver Fluency for Coding across Mercy's network of 26 hospitals and clinics. Based in Chesterfield, Mo., Mercy serves hundreds of communities across the Midwest with 4,600 patient beds.

M*Modal Fluency for Coding is a web-based coding application and workflow platform that is ICD-10 compliant, according to the Franklin, Tenn.-based company. The application consolidates critical patient information in the cloud through features such as review aids, alerts on incomplete documentation and case prioritization.

Editorial Staff

Related Content

10 signs AI is ‘eating the world (of venture capital)’
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy
Healthcare AI regulation needs nuance, balance: Research review
ICU diary-keeping: There’s an AI for that
Stanford HAI lookback: Best-read blog posts of 2024
Providers, payers share actionable experiences involving healthcare AI

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.